EC Gynaecology

Review Article Volume 12 Issue 10 - 2023

A Review of Diabetes Technology During Pregnancy in Women with Pregestational Diabetes Mellitus

Ioanna Katehis1*, Maria Patruno2, Andreas Pfützner3 and Anastasios Manessis2,4

1Department of Obstetrics and Gynecology, NYU Grossman Long Island School of Medicine, Mineola, NY, USA
2Endocrine Associates of West Village PC, Long Island City, NY, USA
3Pfützner Science and Health Institute, Mainz, Germany
4Division of Endocrine, Diabetes and Metabolism, NYU Grossman School of Medicine, New York, NY, USA
*Corresponding Author: Ioanna Katehis, Department of Obstetrics and Gynecology, NYU Grossman Long Island School of Medicine, Mineola, NY, USA.
Received: September 13, 2023; Published: September 29, 2023




Diabetes technology is the use of devices such as continuous glucose monitoring (CGM) systems, continuous subcutaneous insulin infusion (CSII) pumps, and hybrid closed-loop systems with a goal to help manage blood glucose levels, prevent diabetes complications, and improve the quality of life of patients burdened by this disease. The use of diabetes technology is long-standing, as clinicians have continued to study these devices to establish a safe and accurate method of glucose control for patients with pregestational diabetes during pregnancy. Diabetes technology has advanced dramatically within the last decade, making it imperative to establish safety and accuracy during pregnancy in patients with pregestational diabetes. The purpose this literature review is to provide the field of Obstetrics and Gynecology with evidence-based maternal fetal medicine on the use of diabetes technology in these patients, especially if they have been on these devices with excellent glycemic control prior to pregnancy. This will hopefully be helpful to Obstetricians and Gynecologists to determine when diabetes technology is an appropriate option for management of their patients with pregestational diabetes to improve maternal and neonatal health outcomes.

 Keywords: Diabetes Technology; Continuous Glucose Monitoring (CGM); Continuous Subcutaneous Insulin Infusion (CSII); Hybrid Closed-Loop; Pregnancy; Pregestational Diabetes; Type 1 Diabetes

  1. Azeez O., et al. “Hypertension and Diabetes in Non-Pregnant Women of Reproductive Age in the United States”. Preventing Chronic Disease 16 (2019): E146.
  2. Vargas R., et al. “Type 1 diabetes mellitus and pregnancy”. Reviews in Obstetrics and Gynecology3 (2010): 92-100.
  3. Galicia-Garcia U., et al. “Pathophysiology of Type 2 Diabetes Mellitus”. International Journal of Molecular Sciences17 (2020): 6275.
  4. Obstetrics and Gynecology. ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus 132.6 (2018): e228-e248.
  5. Soma-Pillay P., et al. “Physiological changes in pregnancy”. The Cardiovascular Journal of Africa2 (2016): 89-94.
  6. Cunningham FG., et al. “Diabetes Mellitus”. In Williams obstetrics. essay, McGraw Hill (2014).
  7. Kampmann U., et al. “Determinants of Maternal Insulin Resistance during Pregnancy: An Updated Overview”. Journal of Diabetes Research (2019): 5320156.
  8. Pregnancy with type 1 or type 2 diabetes. ACOG. (n.d.) (2022).
  9. Lekšić G., et al. “Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion-Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?” International Journal of Environmental Research and Public Health18 (2020): 6566.
  10. Castorino K., et al. “Insulin pumps in pregnancy: using technology to achieve normoglycemia in women with diabetes”. Current Diabetes Reports1 (2012): 53-59.
  11. Henshaw SK. “Unintended pregnancy in the United States”. Guttmacher Institute (2016).
  12. Pfützner A. “Diabetes Technology”. Endocrine Development 31 (2016): 57-83.
  13. NICE diabetes in pregnancy guideline. Guidelines (2022).
  14. Pickup J. “Insulin pump therapy: pros and cons of continuous infusion”. Prescribing in Practice (2009).
  15. Bruttomesso D., et al. “Italian Group for Continuous Subcutaneous Insulin Infusion in Pregnancy. Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine-MDI)”. Diabetes and Metabolism Journal5 (2011): 426-431.
  16. Smrz S., et al. “Difference in Glycemic Profile with the Pump vs Multiple Daily Injections in Treating Type 1 Diabetes in Pregnancy [32F]”. Obstetrics and Gynecology1 (2019): 70S-71S.
  17. Prior A., et al. “Insulin Requirements by Multiple Daily Injections Versus Pump in Women with Type 1 Diabetes Mellitus [22A]”. Obstetrics and Gynecology1 (2019): 16S-16S.
  18. Mello G., et al. “Continuous subcutaneous insulin infusion (CSII) versus multiple daily injections (MDI) of rapid-acting insulin analogues and detemir in type 1 diabetic (T1D) pregnant women”. Journal of Maternal-Fetal and Neonatal Medicine3 (2015): 276-280.
  19. Jotic A., et al. “Evaluation of Glycaemic Control, Glucose Variability and Hypoglycaemia on Long-Term Continuous Subcutaneous Infusion vs. Multiple Daily Injections: Observational Study in Pregnancies with Pre-Existing Type 1 Diabetes”. Diabetes Therapy4 (2020): 845-858.
  20. Drever E., et al. “Insulin pump use compared with intravenous insulin during labour and delivery: the INSPIRED observational cohort study”. Diabetic Medicine9 (2016): 1253-1259.
  21. Mantaj U., et al. “Continuous subcutaneous insulin infusion reduces neonatal risk in pregnant women with type 1 diabetes mellitus”. Ginekologia Polska3 (2019): 154-160.
  22. Talaviya PA., et al. “Pregnancy outcome and glycemic control in women with type 1 diabetes: a retrospective comparison between CSII and MDI treatment”. Diabetology and Metabolic Syndrome2 (2013): 68-71.
  23. Mourou L., et al. “Assessment of the effect of pregnancy planning in women with type 1 diabetes treated by insulin pump”. Acta Diabetologica3 (2021): 355-362.
  24. American Diabetes Association. “Standards of Medical Care in Diabetes – 2010”. Diabetes Care1 (2010): S11-S61.
  25. Ida S., et al. “Utility of real-time and retrospective continuous glucose monitoring in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials”. Journal of Diabetes Research (2019).
  26. Yamamoto JM and Murphy HR. “Benefits of Real-Time Continuous Glucose Monitoring in Pregnancy”. Diabetes Technology and TherapeuticsS1 (2021): S8-S14.
  27. Battelino T., et al. “Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range”. Diabetes Care (2019).
  28. Feig D., et al. “Continuous Glucose Monitoring in Pregnant Women with Type 1 Diabetes (CONCEPTT): A Multicentre International Randomized Controlled Trial”. Obstetric Anesthesia Digest3 (2018): 139-139.
  29. Lason I., et al. “Continuous glucose monitoring and insulin pump therapy in pregnant women with type 1 diabetes mellitus”. Ginekologia Polska (2021).
  30. Polsky S., et al. “Continuous glucose monitor use with and without remote monitoring in pregnant women with type 1 diabetes: A pilot study”. PLoS One4 (2020): e0230476.
  31. Voormolen DN., et al. “Continous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial”. Diabetes, Obesity and Metabolism8 (2018): 1894-1902.
  32. Garcia-Moreno RM., et al. “Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials”. Diabetic Medicine14703 (2021).
  33. Murphy HR., et al. “Closed-loop insulin delivery during pregnancy complicated by type 1 diabetes”. Diabetes Care2 (2011): 406-411.
  34. Polsky S. “Hybrid Closed-Loop Therapy in Pregnancy: Achieve Targets in Diabetes Care (ATDC) [PowerPoint slides]”. Practical Ways to Achieve Targets in Diabetes Care (2021).
  35. Murphy HR., et al. “Safety and Efficacy of 24-h Closed-Loop Insulin Delivery in Well-Controlled Pregnant Women With Type 1 Diabetes: A randomized crossover case series”. Diabetes Care23 (2011): 2527-2529.
  36. Stewart Z., et al. “Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes”. The New England Journal of Medicine7 (2016): 644-654.
  37. Stewart Z., et al. “Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women with Type 1 Diabetes: A Randomized Controlled Crossover Trial”. Diabetes Care7 (2018): 1391-1399.

Ioanna Katehis., et al. A Review of Diabetes Technology During Pregnancy in Women with Pregestational Diabetes Mellitus. EC Gynaecology 12.10 (2023): 01-15.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net